Out-licensing

GEMCITABINE (2',2'-difluorodeoxycytidine) is a fluorine- substituted deoxycytidine analog with a broad spectrum of antitumor activity. It is rapidly and extensively deaminated by cytidine deaminase to the inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU). In order to enhance the bioavailability as well as the stability of gemcitabine via oral administration, INNOPHARMAX has applied OralPAS^® technique on gemcitabine to prepare unique oral formulation. OralPAS^® enhances the bioavailability of drugs through solubilization in the excipient matrix or interface and dispersion in the gastrointestinal tract. These characteristics result in faster drug release from nanoparticles in a reproducible manner, which can be designed further to make the release characteristics independent of the gastro-intestinal physiology and the fed/fasted state of the patient. Recently, several in-vitro and in-vivo studies (i.e. pilot tests in rats and dogs) have been done and study goals have been met.  

Patent applications have been filed in US, PCT and Republic of China(Taiwan).

To look for partners around the world to license out or co-develop Inno-D07001(Gemcitabine Oral)